Pharma: Other News To Note
• GE Healthcare, of Chalfont St. Giles, UK, and Eisai Inc., of Woodcliff Lake, N.J., inked a research collaboration agreement for use of the GE Healthcare investigational PET amyloid imaging agent [18]flutemetamol to help select patients for a Phase I trial testing Eisai's E2609, a BACE inhibitor for the potential treatment of Alzheimer's disease.
